Treace Medical Concepts, a medical technology company specializing in surgical treatments for bunions and midfoot deformities, announced it will release its third quarter 2026 financial results on November 6, 2026, before market open. The company will host a conference call at 8:00 am ET to discuss the results, accessible via registration on their investor relations website. Treace is known for its patented Lapiplasty 3D Bunion Correction System and other innovative surgical products. Investors and interested parties are encouraged to visit Treace's website for updates and participate in the call to gain insights into the company's performance and future outlook.
Treace Medical Concepts' upcoming third quarter 2026 financial results are scheduled for release on November 6, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 23, 2026 17:41 WIB: out of 150 priced health-sector US stocks, 42 rose and 97 fell. Notable movers include Moderna, Inc. (MRNA) at USD 194.71 with a 1-day change of -3.91% and Pluang order activity of 71% Sell / 29% Buy, Nuvation Bio Inc. Class A (NUVB) at USD 4.85 with a 1-day change of +3.19%, and Heron Therapeutics Inc (HRTX) at USD 0.30 with a 1-day change of +2.97%.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
